PE20011140A1 - Proceso para preparar forma i cristalina de cabergolina - Google Patents
Proceso para preparar forma i cristalina de cabergolinaInfo
- Publication number
- PE20011140A1 PE20011140A1 PE2001000237A PE2001000237A PE20011140A1 PE 20011140 A1 PE20011140 A1 PE 20011140A1 PE 2001000237 A PE2001000237 A PE 2001000237A PE 2001000237 A PE2001000237 A PE 2001000237A PE 20011140 A1 PE20011140 A1 PE 20011140A1
- Authority
- PE
- Peru
- Prior art keywords
- cabergolin
- cabergoline
- crystaline
- dat2
- receptors
- Prior art date
Links
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title abstract 3
- 229960004596 cabergoline Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- 102000003946 Prolactin Human genes 0.000 abstract 2
- 108010057464 Prolactin Proteins 0.000 abstract 2
- 229940097325 prolactin Drugs 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0007308.0A GB0007308D0 (en) | 2000-03-24 | 2000-03-24 | Process for preparing crystalline form | of cabergoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011140A1 true PE20011140A1 (es) | 2001-11-01 |
Family
ID=9888433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000237A PE20011140A1 (es) | 2000-03-24 | 2001-03-13 | Proceso para preparar forma i cristalina de cabergolina |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US6727363B2 (enExample) |
| EP (1) | EP1272489B1 (enExample) |
| JP (1) | JP4184666B2 (enExample) |
| KR (1) | KR100827558B1 (enExample) |
| CN (1) | CN1188412C (enExample) |
| AR (1) | AR032449A1 (enExample) |
| AT (1) | ATE250601T1 (enExample) |
| AU (2) | AU780747B2 (enExample) |
| BR (1) | BR0109507A (enExample) |
| CA (1) | CA2402836A1 (enExample) |
| CZ (1) | CZ20023176A3 (enExample) |
| DE (1) | DE60100858T2 (enExample) |
| DK (1) | DK1272489T3 (enExample) |
| EA (1) | EA005928B1 (enExample) |
| EE (1) | EE05088B1 (enExample) |
| ES (1) | ES2208602T3 (enExample) |
| GB (1) | GB0007308D0 (enExample) |
| HK (1) | HK1052348B (enExample) |
| HU (1) | HUP0300591A3 (enExample) |
| IL (2) | IL150985A0 (enExample) |
| MX (1) | MXPA02009283A (enExample) |
| MY (1) | MY134189A (enExample) |
| NO (1) | NO20024321D0 (enExample) |
| NZ (1) | NZ521316A (enExample) |
| PE (1) | PE20011140A1 (enExample) |
| PL (1) | PL358253A1 (enExample) |
| PT (1) | PT1272489E (enExample) |
| SI (1) | SI1272489T1 (enExample) |
| SK (1) | SK13582002A3 (enExample) |
| WO (1) | WO2001070740A1 (enExample) |
| ZA (1) | ZA200206045B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0007308D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
| GB0007307D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
| DE10066158B4 (de) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| CA2478149A1 (en) * | 2002-03-15 | 2003-09-25 | Pharmacia Corporation | Process for preparing crystalline form i of cabergoline |
| PL374503A1 (en) * | 2002-03-15 | 2005-10-31 | Pharmacia Corporation | Process for preparing crystalline form i of cabergoline |
| IL155545A (en) * | 2003-04-21 | 2009-12-24 | Finetech Pharmaceutical Ltd | Solvate form of cabergoline |
| JP2007501274A (ja) * | 2003-05-08 | 2007-01-25 | イヴァックス ファーマシューティカルズ エス．アール．オー． | カベルゴリンの多形体 |
| GB0409785D0 (en) * | 2004-04-30 | 2004-06-09 | Resolution Chemicals Ltd | Preparation of cabergoline |
| GB0515430D0 (en) * | 2005-07-27 | 2005-08-31 | Resolution Chemicals Ltd | Preparation of cabergoline |
| GB0505965D0 (en) | 2005-03-23 | 2005-04-27 | Resolution Chemicals Ltd | Preparation of cabergoline |
| US7339060B2 (en) | 2005-03-23 | 2008-03-04 | Resolution Chemicals, Ltd. | Preparation of cabergoline |
| EP1925616A1 (en) * | 2006-10-26 | 2008-05-28 | LEK Pharmaceuticals D.D. | Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline |
| EP1953157A1 (en) | 2007-01-31 | 2008-08-06 | LEK Pharmaceuticals D.D. | New crystal form of cabergoline |
| EP2185169A2 (en) * | 2007-08-29 | 2010-05-19 | Max Zeller Söhne AG | Use of vitex agnus castus extracts for preparing a medicament |
| EP4074552B1 (en) * | 2021-04-16 | 2024-04-03 | Thermo King LLC | Electrical connection unit |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3019322A1 (de) | 1980-05-21 | 1981-12-03 | Merck Patent Gmbh, 6100 Darmstadt | Psychopharmakon sowie verwendung von adenosinderivaten |
| US4526892A (en) | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| GB2103603B (en) * | 1981-08-11 | 1985-04-11 | Erba Farmitalia | Ergoline derivatives |
| GB9205439D0 (en) | 1992-03-12 | 1992-04-22 | Erba Carlo Spa | Process for the synthesis of ergoline derivatives |
| CA2146006C (en) | 1993-08-18 | 2004-10-12 | Louis Desantis, Jr. | Use of ergoline derivatives for the treatment of glaucoma |
| US20020010197A1 (en) | 1998-01-13 | 2002-01-24 | John Dixon | Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity |
| WO1999048484A2 (en) | 1998-03-27 | 1999-09-30 | Pharmacia & Upjohn Company | Use of cabergoline in the treatment of restless legs syndrome |
| GB0007309D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
| GB0007308D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
| GB0007307D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
-
2000
- 2000-03-24 GB GBGB0007308.0A patent/GB0007308D0/en not_active Ceased
-
2001
- 2001-03-13 PE PE2001000237A patent/PE20011140A1/es not_active Application Discontinuation
- 2001-03-19 AR ARP010101263A patent/AR032449A1/es unknown
- 2001-03-19 HK HK03104554.7A patent/HK1052348B/zh not_active IP Right Cessation
- 2001-03-19 DK DK01936098T patent/DK1272489T3/da active
- 2001-03-19 HU HU0300591A patent/HUP0300591A3/hu unknown
- 2001-03-19 NZ NZ521316A patent/NZ521316A/en unknown
- 2001-03-19 IL IL15098501A patent/IL150985A0/xx active IP Right Grant
- 2001-03-19 WO PCT/EP2001/003099 patent/WO2001070740A1/en not_active Ceased
- 2001-03-19 EA EA200201016A patent/EA005928B1/ru unknown
- 2001-03-19 JP JP2001568941A patent/JP4184666B2/ja not_active Expired - Fee Related
- 2001-03-19 EP EP01936098A patent/EP1272489B1/en not_active Expired - Lifetime
- 2001-03-19 ES ES01936098T patent/ES2208602T3/es not_active Expired - Lifetime
- 2001-03-19 SK SK1358-2002A patent/SK13582002A3/sk unknown
- 2001-03-19 CZ CZ20023176A patent/CZ20023176A3/cs unknown
- 2001-03-19 DE DE60100858T patent/DE60100858T2/de not_active Expired - Fee Related
- 2001-03-19 US US10/239,636 patent/US6727363B2/en not_active Expired - Fee Related
- 2001-03-19 MX MXPA02009283A patent/MXPA02009283A/es active IP Right Grant
- 2001-03-19 PL PL01358253A patent/PL358253A1/xx not_active Application Discontinuation
- 2001-03-19 KR KR1020027012590A patent/KR100827558B1/ko not_active Expired - Fee Related
- 2001-03-19 PT PT01936098T patent/PT1272489E/pt unknown
- 2001-03-19 AT AT01936098T patent/ATE250601T1/de not_active IP Right Cessation
- 2001-03-19 SI SI200130045T patent/SI1272489T1/xx unknown
- 2001-03-19 AU AU62110/01A patent/AU780747B2/en not_active Ceased
- 2001-03-19 BR BR0109507-2A patent/BR0109507A/pt not_active Application Discontinuation
- 2001-03-19 CN CNB018070051A patent/CN1188412C/zh not_active Expired - Fee Related
- 2001-03-19 EE EEP200200545A patent/EE05088B1/xx not_active IP Right Cessation
- 2001-03-19 CA CA002402836A patent/CA2402836A1/en not_active Withdrawn
- 2001-03-22 MY MYPI20011364A patent/MY134189A/en unknown
-
2002
- 2002-07-29 ZA ZA200206045A patent/ZA200206045B/xx unknown
- 2002-07-30 IL IL150985A patent/IL150985A/en not_active IP Right Cessation
- 2002-09-10 NO NO20024321A patent/NO20024321D0/no not_active Application Discontinuation
-
2003
- 2003-10-31 US US10/698,737 patent/US6953854B2/en not_active Expired - Fee Related
-
2005
- 2005-07-14 AU AU2005203071A patent/AU2005203071B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20011140A1 (es) | Proceso para preparar forma i cristalina de cabergolina | |
| JAVIDNIA et al. | Composition of the volatile oil of Achillea wilhelmsii C. Koch from Iran | |
| CN101735888B (zh) | 一种铁皮石斛花挥发油的提取方法 | |
| MY155394A (en) | Muscadine composition with improved anti-oxidant activity | |
| BRPI0912014A2 (pt) | processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização | |
| CN101581648B (zh) | 一种测定配方烟丝中薄片丝掺用比例的方法 | |
| NZ590682A (en) | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide | |
| TNSN07013A1 (en) | Anti-histaminic composition | |
| PH12012501619A1 (en) | Synthesis of magnolol and its analogue compounds | |
| RU2010149293A (ru) | Жевательная твердая композиция и способ подавления развития streptococcus mutans | |
| CN102807692A (zh) | 一种再生橡胶生产用的软化剂 | |
| BR112022008930A2 (pt) | Formulação em pó seco aromatizada com tabaco melhorada | |
| RU2014133099A (ru) | Применение косточки авокадо для получения масла авокадо, обогащенного алифатическими многоатомными спиртами и/или их ацетилированными производными | |
| EA201400802A1 (ru) | Способ приготовления курительной композиции без табака для кальяна | |
| PE20011087A1 (es) | Forma ii cristalina de cabergolina | |
| TW200604209A (en) | Moisture retention polymer compound | |
| GB0118300D0 (en) | Formulations | |
| PE20141531A1 (es) | Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos | |
| PE108798A1 (es) | Compuestos de naftilo, intermedios, composiciones y procedimientos de uso | |
| Upadhye et al. | Antimigraine activity study of Moringa oleifera leaf juice | |
| Saqib et al. | DFT for exploring the antioxidant potential of homogentisic and orsellinic acids | |
| PE20001487A1 (es) | 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles sustituidos con n-(5-fenil-tetrahidrofuranil) metilo y n-(6-fenil-tetrahidropiranil) metilo; procedimientos para prepararlos y su empleo como composiciones farmaceuticas | |
| CN101773283A (zh) | 一种组合膨胀烟丝 | |
| CN102311838A (zh) | 一种低硫柴油润滑添加剂及其制备方法与应用 | |
| EP2499123B1 (en) | Anti-inflammatory compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |